open access

Vol 9, No 1 (2006)
Published online: 2006-01-25
Submitted: 2012-01-23
Get Citation

Specific 99mtc-hepida hepatic clearance - essential value ranges from a clinical stand-point

Izabela Frieske, Marian J. Surma, Małgorzata Bieńkiewicz, Jacek Kuśmierek
Nucl. Med. Rev 2006;9(1):56-59.

open access

Vol 9, No 1 (2006)
Published online: 2006-01-25
Submitted: 2012-01-23

Abstract

BACKGROUND: Determinations of plasma 99mTc-HEPIDA clearance (ClPl) have been performed in some centres for 30 years to assess liver parenchyma damage, mostly for monitoring of organ performance in the course of various diseases. The main disadvantage of such a procedure rests with the fact that elimination of the compound from the system occurs not only via the liver and gall ducts, but also via the urinary route; the contribution of the latter compound being quite variable. This circumstance may lead to false assessment of liver parenchyma performance. A method has been developed therefore for assessment of specific hepatic clearance of 99mTc-HEPIDA (ClHp). Using this method it was demonstrated that results of ClHp correlated better with independently assessed degrees of liver impairment than did the values of ClPl.
MATERIAL AND METHODS: To delineate ranges of ClHp that would provide valuable clinical information 134 individuals were studied, of whom 48 served as healthy controls and 86 had varying degrees of livers function impairment, resulting from various chronic diseases affecting the organs functional capacity. The latter was assessed on the basis of a series of commonly used biochemical indicators.
RESULTS AND CONCLUSIONS: For delineation of meaningful ranges of 99mTc-HEPIDA specific hepatic clearance ROC curve method was used. The following results were obtained: ClHp ≥ 150 ml min-1 1.72 m-2 - excludes with high probability presence of substantial liver parenchyma damage; ClHp ≤ 120 ml min-1 1.72m-2 - indicates a substantial impairment of liver function (damage). Values of ClHp ≤ 90 ml min-1 1.72 m-2 are highly specific for serious liver damage, of intensity typical for cirrhosis of the organ.

Abstract

BACKGROUND: Determinations of plasma 99mTc-HEPIDA clearance (ClPl) have been performed in some centres for 30 years to assess liver parenchyma damage, mostly for monitoring of organ performance in the course of various diseases. The main disadvantage of such a procedure rests with the fact that elimination of the compound from the system occurs not only via the liver and gall ducts, but also via the urinary route; the contribution of the latter compound being quite variable. This circumstance may lead to false assessment of liver parenchyma performance. A method has been developed therefore for assessment of specific hepatic clearance of 99mTc-HEPIDA (ClHp). Using this method it was demonstrated that results of ClHp correlated better with independently assessed degrees of liver impairment than did the values of ClPl.
MATERIAL AND METHODS: To delineate ranges of ClHp that would provide valuable clinical information 134 individuals were studied, of whom 48 served as healthy controls and 86 had varying degrees of livers function impairment, resulting from various chronic diseases affecting the organs functional capacity. The latter was assessed on the basis of a series of commonly used biochemical indicators.
RESULTS AND CONCLUSIONS: For delineation of meaningful ranges of 99mTc-HEPIDA specific hepatic clearance ROC curve method was used. The following results were obtained: ClHp ≥ 150 ml min-1 1.72 m-2 - excludes with high probability presence of substantial liver parenchyma damage; ClHp ≤ 120 ml min-1 1.72m-2 - indicates a substantial impairment of liver function (damage). Values of ClHp ≤ 90 ml min-1 1.72 m-2 are highly specific for serious liver damage, of intensity typical for cirrhosis of the organ.
Get Citation

Keywords

99mTc-HEPIDA plasma clearance; specific 99mTc-HEPIDA hepatic clearance; clinically essential range

About this article
Title

Specific 99mtc-hepida hepatic clearance - essential value ranges from a clinical stand-point

Journal

Nuclear Medicine Review

Issue

Vol 9, No 1 (2006)

Pages

56-59

Published online

2006-01-25

Bibliographic record

Nucl. Med. Rev 2006;9(1):56-59.

Keywords

99mTc-HEPIDA plasma clearance
specific 99mTc-HEPIDA hepatic clearance
clinically essential range

Authors

Izabela Frieske
Marian J. Surma
Małgorzata Bieńkiewicz
Jacek Kuśmierek

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl